2National Institutes of Health. National diabetes statistics 2007 Wprevalence of diagnosed and undiagnosed diabetes in the United States, all ages, 2007 [ EB/OL]. [2009 - 08 - 14]. http ://diabetes. niddk. nih. gov/dm/pubs/statistics/#allages.
3RUSSELL-JONES D. Molecular,pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue[ J]. Mol Cell Endocrinol,2009,297 ( 12 ) : 137 - 140.
4NAUCK MA, HEIMESAAT MM, BEHLE K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemie,stepped hypoglycemie clamp experiments in healthy volunteers[J]. J Clin Endocrinol Metab, 2002,87 (3) : 1239 - 1246.
5ZINMAN B, GERICH J, BUSE JB,et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes(LEAD-4 Met + TZD ) [J]. Diabetes Care, 2009, 32 (7) : 1224 -1230.
6BUSE JB, ROSENSTOCK J, SESTI G,et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial ( LEAD- 6)[J]. Lancet,2009,374(4): 39-47.
7NAUCK M, MARRE M. Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits [ J ]. Postgrad Med, 2009,121(3): 5-15.
8ASTRUP A, ROSSNER S, VAN GAAL L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind,placebo-controlled study [ J ]. Lancet, 2009, 374 ( 9701 ) : 1606 - 1616.
9BOSE AK, MOCANU MM, CARR RD, et al. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury[ J]. Diabetes,2005,54(1) :146 - 151.
10MEECE J, FACA BS. Pharmacokinetics and pharmacodynamics of liraglutide, a long-acting, potent glueagon-like peptide-1 analog [J]. Pharmacotherapy, 2009,29(12) :33S-42S.
